Please provide your email address to receive an email when new articles are posted on . Of 146 patients treated with dupilumab, 127 achieved disease control within 4 weeks. Complete remission was ...
Please provide your email address to receive an email when new articles are posted on . Nomacopan was well tolerated and beneficial in patients with bullous pemphigoid, according to phase 2a clinical ...
A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...
Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a ...
Bullous pemphigoid, an immune-mediated condition characterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs ...
bullous pemphigoid leg The relationship between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Regardless of the diagnosis of type 2 diabetes, patients with bullous ...
DelveInsight’s Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Bullous Pemphigoid , historical and forecasted epidemiology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback